
Commentary|Videos|December 12, 2024
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer
Author(s)Azka Ali, MD
Fact checked by: Ashling Wahner , Chris Ryan
Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.
Advertisement
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute, discusses updated findings from the phase 3 S0221 trial (NCT00070564) investigating alternative adjuvant anthracycline and taxane dosing schedules in patients with high-risk, early breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































